| Abstrakt: |
A study conducted by the University of Washington explores the sustainability of the United States biosimilars market, highlighting the potential cost-saving benefits of biosimilars compared to reference biologic therapies. The research emphasizes the importance of establishing sustainable market conditions to ensure continued cost savings and access to cutting-edge biologic therapies. Stakeholders, including health care payers, providers, and manufacturers, discussed key opportunities and threats to the sustainability of the biosimilar market, proposing policy solutions to address these challenges. The study concludes with optimism that informed decision-making and collaboration among stakeholders can lead to a robust and sustainable biosimilars market in the United States. [Extracted from the article] |
